Not available
Quote | Curis Inc. (NASDAQ:CRIS)
Last: | $6.12 |
---|---|
Change Percent: | -1.5% |
Open: | $6.11 |
Close: | $6.12 |
High: | $6.28 |
Low: | $6 |
Volume: | 11,489 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Curis Inc. (NASDAQ:CRIS)
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development ...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Curis Inc. (NASDAQ:CRIS)
Subject | By | Source | When |
---|---|---|---|
great article | blue point | investorshub | 07/05/2023 11:36:54 AM |
great news | 4lmaral | investorshub | 07/04/2023 12:32:39 PM |
$CRIS great news | stockguard | investorshub | 07/03/2023 1:26:18 PM |
short squeeze | subslover | investorshub | 06/30/2023 9:05:46 PM |
$CRIS The trading up | subslover | investorshub | 06/30/2023 4:52:24 AM |
News, Short Squeeze, Breakout and More Instantly...
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire LEXINGTON, Mass. , July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development ...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...